
Experimental drug helps patients lose nearly a quarter of body weight in early trials
Fox News
Novo Nordisk's experimental pill amycretin shows promising results in early trials, with participants losing up to 24.3% of body weight by targeting two hunger hormones.
"Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule." Melissa Rudy is senior health editor and a member of the lifestyle team at Fox News Digital. Story tips can be sent to melissa.rudy@fox.com.
"Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule," Martin Holst Lange, executive vice president and head of development at Novo Nordisk, previously said in a statement sent to Fox News Digital.
More Related News













